Unlocking the Value of RSV Adult Vaccination With Adjuvanted RSVpreF3 Vaccine in Spain: A Return on Investment Analysis Using an Integrated Actuarial Macroeconomic Model
Author(s)
Eleftherios Zarkadoulas, MBA, FHAS, CERA1, Andrea GARCIA I LURI, MSc2, Foteini Gkalapi, MD3, Ru HAN, PhD1, Nidhi Dani, MBA4, Nikos Kotsopoulos, MSc, PhD5, LAURA VALLEJO, MSc2.
1GSK, Wavre, Belgium, 2GSK, Tres Cantos, Spain, 3GSK, Athens, Greece, 4GSK, Basel, Switzerland, 5Univesity of Groningen, Groningen, Netherlands.
1GSK, Wavre, Belgium, 2GSK, Tres Cantos, Spain, 3GSK, Athens, Greece, 4GSK, Basel, Switzerland, 5Univesity of Groningen, Groningen, Netherlands.
OBJECTIVES: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in adults particularly affecting those with underlying health-conditions, imposing a substantial burden on the Spanish healthcare system, contributing to a diminished quality of life for patients, and productivity losses for the entire economy. Vaccination programmes are effective prevention strategies when adequately informed through economic evaluation. This study evaluates the return on investment (ROI) of an RSV vaccination programme with the adjuvanted RSVPreF3 vaccine in both general and high-risk populations aged ≥ 60 years in Spain, from a societal perspective.
METHODS: An integrated actuarial and macroeconomic model was developed to assess the ROI of the adjuvanted RSVPreF3 vaccination over a 10-year time horizon. The actuarial component projected age-specific RSV incidence, healthcare resource utilisation, and direct medical costs. The macroeconomic module estimated indirect costs, productivity losses and broader economic impacts (fiscal revenue and gross domestic product [GDP] gains). Quality-adjusted life-years (QALYs) gained through vaccination were monetized using willingness-to-pay thresholds of 1-3 times the GDP/capita. ROI was calculated as the ratio of total monetized benefits—including healthcare savings and QALY gains—to vaccination programme costs. Sensitivity analyses on the significant parameters were performed to evaluate the model’s robustness.
RESULTS: From a societal perspective, RSV vaccination in general population aged ≥60 delivered an ROI of €5.6-15.6 per €1 invested depending on the QALY evaluation, with high internal rates of return. Returns were more favourable among high-risk population. In both groups, the primary drivers were economic productivity gains and the monetized value of improved health outcomes.
CONCLUSIONS: From a societal perspective a vaccination programme with the adjuvanted RSVPreF3 vaccine in Spain would constitute a high-value public health investment, yielding positive returns. The results support informed decisions on public investment in RSV immunisation as a cost-saving strategy that delivers both substantial health benefits and economic gains.
METHODS: An integrated actuarial and macroeconomic model was developed to assess the ROI of the adjuvanted RSVPreF3 vaccination over a 10-year time horizon. The actuarial component projected age-specific RSV incidence, healthcare resource utilisation, and direct medical costs. The macroeconomic module estimated indirect costs, productivity losses and broader economic impacts (fiscal revenue and gross domestic product [GDP] gains). Quality-adjusted life-years (QALYs) gained through vaccination were monetized using willingness-to-pay thresholds of 1-3 times the GDP/capita. ROI was calculated as the ratio of total monetized benefits—including healthcare savings and QALY gains—to vaccination programme costs. Sensitivity analyses on the significant parameters were performed to evaluate the model’s robustness.
RESULTS: From a societal perspective, RSV vaccination in general population aged ≥60 delivered an ROI of €5.6-15.6 per €1 invested depending on the QALY evaluation, with high internal rates of return. Returns were more favourable among high-risk population. In both groups, the primary drivers were economic productivity gains and the monetized value of improved health outcomes.
CONCLUSIONS: From a societal perspective a vaccination programme with the adjuvanted RSVPreF3 vaccine in Spain would constitute a high-value public health investment, yielding positive returns. The results support informed decisions on public investment in RSV immunisation as a cost-saving strategy that delivers both substantial health benefits and economic gains.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE743
Topic
Economic Evaluation
Topic Subcategory
Novel & Social Elements of Value
Disease
Vaccines